Good Evening Market Enthusiast,
This is a real clinical-stage setup with fresh data, multiple 2026 milestones, and one valuation disconnect that is hard to ignore.
Here is the part that jumps off the page:
Recent levels have been around $0.30.
The average analyst target
is $6.50.
The high target is $9, with the most recent coming from D. Boral Capital.
That is the kind of spread that makes people stop scrolling. 🧬
Tomorrow morning, we are releasing our updated breakdown on a clinical-stage company working across skin cancer, prostate cancer, rare disease, and AI-enabled clinical development.
The headline story centers on
a non-invasive microneedle platform being evaluated for nodular basal cell carcinoma, the most common form of skin cancer.
The company has already reported Phase 2 data showing up to 73% clinical clearance in the highest-dose cohort.
Its newest expanded analysis added more depth to the story, including a positive dose-response profile and a lead 200µg regimen now being positioned
around future late-stage planning.
That is only one side of the setup.
The company also has a next-generation GnRH antagonist platform targeting advanced prostate cancer and acute urinary retention recurrence prevention, with FDA clearance already received to proceed with a Phase 2b dose optimization study in advanced prostate cancer.
Two clinical platforms.
Multiple 2026 milestones. 💥
Recent levels near $0.30.
Average target of $6.50.
High target of $9.
The full release goes live tomorrow morning at 8AM ET.
This one is already on our radar.
Tomorrow at 8AM ET, you will see why.
Max Masters
Co-founder, Market Tips Newsletter
